Chronic Heart Failure
Conditions
Keywords
Chronic heart failure, candesartan cilexetil, clinical signs, symptoms
Brief summary
The purpose of this study is to determine whether treatment with candesartan cilexetil for at least 6 months in patients with chronic heart failure improves clinical signs and symptoms of chronic heart failure.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with diagnosed chronic heart failure * Patients treated for at least 6 months with candesartan cilexetil * Signed Informed consent
Exclusion criteria
* Hypersensitivity to candesartan cilexetil * Pregnancy / lactation * Severe hepatic impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate clinical signs and symptoms of chronic heart failure (in terms of NYHA status, fluid retention and tiredness/fatigue) after at least 6 months of treatment with candesartan cilexetil | 1 visit (after at least 6 months of treatment) |
Secondary
| Measure | Time frame |
|---|---|
| To gain insight into usage of candesartan cilexetil in real life for chronic heart failure in Croatia | 1 visit (after at least 6 months of treatment) |
| To evaluate patient's compliance with prescribed treatment | 1 visit (after at least 6 months of treatment) |
| To evaluate ventricular function after at least 6 months of treatment with candesartan cilexetil | 1 visit (after at least 6 months of treatment) |
Countries
Croatia
Outcome results
None listed